AU2003267751A1 - Use of epothilone derivatives for the treatment of hyperparathyroidism - Google Patents

Use of epothilone derivatives for the treatment of hyperparathyroidism

Info

Publication number
AU2003267751A1
AU2003267751A1 AU2003267751A AU2003267751A AU2003267751A1 AU 2003267751 A1 AU2003267751 A1 AU 2003267751A1 AU 2003267751 A AU2003267751 A AU 2003267751A AU 2003267751 A AU2003267751 A AU 2003267751A AU 2003267751 A1 AU2003267751 A1 AU 2003267751A1
Authority
AU
Australia
Prior art keywords
hyperparathyroidism
treatment
epothilone derivatives
animal
epothilone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267751A
Other languages
English (en)
Inventor
Eugene A. Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2003267751A1 publication Critical patent/AU2003267751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003267751A 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism Abandoned AU2003267751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US60/418,592 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (1)

Publication Number Publication Date
AU2003267751A1 true AU2003267751A1 (en) 2004-05-04

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267751A Abandoned AU2003267751A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Country Status (15)

Country Link
US (2) US20060142354A1 (cg-RX-API-DMAC10.html)
EP (1) EP1553938B1 (cg-RX-API-DMAC10.html)
JP (1) JP4672368B2 (cg-RX-API-DMAC10.html)
CN (1) CN1297269C (cg-RX-API-DMAC10.html)
AT (1) ATE350034T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003267751A1 (cg-RX-API-DMAC10.html)
BR (1) BR0315293A (cg-RX-API-DMAC10.html)
CA (1) CA2501717C (cg-RX-API-DMAC10.html)
CY (1) CY1106385T1 (cg-RX-API-DMAC10.html)
DE (1) DE60310975T2 (cg-RX-API-DMAC10.html)
DK (1) DK1553938T3 (cg-RX-API-DMAC10.html)
ES (1) ES2279139T3 (cg-RX-API-DMAC10.html)
PT (1) PT1553938E (cg-RX-API-DMAC10.html)
SI (1) SI1553938T1 (cg-RX-API-DMAC10.html)
WO (1) WO2004035050A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
KR20080016756A (ko) * 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
DE60310975D1 (de) 2007-02-15
SI1553938T1 (sl) 2007-06-30
JP2006504751A (ja) 2006-02-09
JP4672368B2 (ja) 2011-04-20
BR0315293A (pt) 2005-08-30
US20060142354A1 (en) 2006-06-29
WO2004035050A1 (en) 2004-04-29
CY1106385T1 (el) 2011-10-12
CN1297269C (zh) 2007-01-31
US20110152329A1 (en) 2011-06-23
ATE350034T1 (de) 2007-01-15
PT1553938E (pt) 2007-03-30
EP1553938A1 (en) 2005-07-20
DK1553938T3 (da) 2007-03-26
EP1553938B1 (en) 2007-01-03
ES2279139T3 (es) 2007-08-16
CN1703217A (zh) 2005-11-30
CA2501717A1 (en) 2004-04-29
HK1080768A1 (en) 2006-05-04
DE60310975T2 (de) 2007-07-12
CA2501717C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
ATE440603T1 (de) 8-hydroxychinolinderivate
SI1940786T1 (sl) Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MY138352A (en) Benzothiazole derivatives
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2003080582A3 (de) Fredericamycin-derivate
TW200420549A (en) Thiazole derivatives
GB0225475D0 (en) Therapeutic agents
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
GB0112348D0 (en) Compounds
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
IN2005KO00312A (cg-RX-API-DMAC10.html)
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2004044174A3 (en) Topoisomerase-targeting agents
SI1553938T1 (sl) Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
AU2368802A (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase